Beam Therapeutics Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Beam Therapeutics Inc 公司

Beam Therapeutics Inc. 是一家通過鹼基編輯開發精準基因藥物的生物技術公司。該公司的基因編輯技術套件以鹼基編輯爲基礎，該技術旨在實現目標基因組序列的精確、可預測和有效的單鹼基變化，而不會在脫氧核糖核酸中造成雙鏈斷裂。其主要項目專注於鐮狀細胞病和 α-1 抗胰蛋白酶缺乏症，同時也在推進其他遺傳疾病以及免疫學/腫瘤學方面的項目。其主要項目包括 BEAM-101、工程幹細胞抗體配對逃避 (ESCAPE)、BEAM-302、BEAM-301 和 BEAM-201。BEAM-101 是一種針對患者的自體造血幹細胞 (HSC) 研究療法。ESCAPE 是一種潛在的無基因毒性 HSC 移植方法。 BEAM-302 是一種靶向肝臟的鹼基編輯試劑脂質納米顆粒製劑。BEAM-201 是一種抗 CD7 CAR-T 候選產品。

Beam Therapeutics Inc簡介



公司代碼BEAM

公司名稱Beam Therapeutics Inc

上市日期Feb 06, 2020

CEOMr. John M. Evans

員工數量483

證券類型Ordinary Share

年結日Feb 06

公司地址238 Main Street

城市CAMBRIDGE

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編02142

電話18573278775

網址https://beamtx.com/

公司代碼BEAM

上市日期Feb 06, 2020

CEOMr. John M. Evans

Beam Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Giuseppe Ciaramella, Ph.D.

President

107.78K

-6.45%

Dr. Amy Simon, M.D.

Chief Medical Officer

1.74K

-97.47%

Dr. John M. Maraganore, Ph.D.

Independent Director

--

Dr. Christine P. Bellon, Ph.D.

Chief Legal Officer and Secretary

--

Mr. Sravan K. Emany

Chief Financial and Principal Financial Officer

--

Mr. John M. Evans

Chief Executive Officer, Principal Accounting Officer, Director

--

Mr. Chirfi Guindo

Independent Director

--

Ms. Christi Shaw

Independent Director

--

Dr. Mark C. Fishman, M.D.

Lead Independent Director

--

Mr. Graham K. Cooper

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Dr. Giuseppe Ciaramella, Ph.D.

President

107.78K

-6.45%

Dr. Amy Simon, M.D.

Chief Medical Officer

1.74K

-97.47%

Dr. John M. Maraganore, Ph.D.

Independent Director

--

Dr. Christine P. Bellon, Ph.D.

Chief Legal Officer and Secretary

--

Mr. Sravan K. Emany

Chief Financial and Principal Financial Officer

--

Mr. John M. Evans

Chief Executive Officer, Principal Accounting Officer, Director

--

收入明細

FY2025Q2

FY2025Q1

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

暫無數據

地區USD

名稱

營收

佔比

United States

8.47M

0.00%

業務

地區

暫無數據

股東統計

更新時間: 8月16日週六

持股股東

股東類型

持股股東

佔比

Fidelity Management & Research Company LLC

12.38%

ARK Investment Management LLC

10.29%

Farallon Capital Management, L.L.C.

9.90%

The Vanguard Group, Inc.

9.58%

BlackRock Institutional Trust Company, N.A.

6.64%

其他

51.21%

持股股東

佔比

Fidelity Management & Research Company LLC

12.38%

ARK Investment Management LLC

10.29%

Farallon Capital Management, L.L.C.

9.90%

The Vanguard Group, Inc.

9.58%

BlackRock Institutional Trust Company, N.A.

6.64%

其他

51.21%

股東類型

持股股東

佔比

Investment Advisor

55.19%

Hedge Fund

20.88%

Investment Advisor/Hedge Fund

19.46%

Venture Capital

4.81%

Research Firm

3.80%

Individual Investor

1.27%

Bank and Trust

0.67%

Pension Fund

0.28%

Family Office

0.06%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

528

106.40M

105.18%

+1.16M

2025Q2

537

101.17M

100.03%

+11.84M

2025Q1

562

100.13M

99.59%

+12.37M

2024Q4

542

80.18M

95.83%

-6.23M

2024Q3

539

78.60M

95.42%

-7.95M

2024Q2

538

78.23M

95.09%

-5.21M

2024Q1

550

76.09M

93.23%

-4.97M

2023Q4

549

75.48M

92.79%

-3.23M

2023Q3

554

74.84M

95.14%

-3.35M

2023Q2

566

72.06M

94.81%

-2.24M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Fidelity Management & Research Company LLC

12.53M

12.38%

+4.93M

+64.83%

Jun 30, 2025

ARK Investment Management LLC

10.41M

10.29%

+1.56M

+17.66%

Jul 31, 2025

Farallon Capital Management, L.L.C.

10.01M

9.9%

+85.00K

+0.86%

Jun 30, 2025

The Vanguard Group, Inc.

9.69M

9.58%

+837.64K

+9.47%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

6.72M

6.64%

-37.63K

-0.56%

Jun 30, 2025

Amova Asset Management Co., Ltd.

4.73M

4.68%

+462.57K

+10.84%

Jun 30, 2025

ARCH Venture Partners

4.54M

4.49%

--

Jun 30, 2025

State Street Global Advisors (US)

3.64M

3.6%

+198.15K

+5.76%

Jun 30, 2025

Bellevue Asset Management AG

2.89M

2.86%

+493.36K

+20.59%

Jun 30, 2025

Kynam Capital Management LP

2.42M

2.39%

-100.52K

-3.99%

Jun 30, 2025

持股ETF



更新時間: 10月6日週一

機構名稱

佔比

ARK Genomic Revolution ETF

3.21%

ARK Innovation ETF

1.71%

WisdomTree BioRevolution Fund

1.69%

Global X Genomics & Biotechnology ETF

1.68%

Virtus LifeSci Biotech Clinical Trials ETF

0.73%

Franklin Genomic Advancements ETF

0.53%

SPDR S&P Biotech ETF

0.49%

Direxion Daily S&P Biotech Bull 3X Shares

0.3%

Invesco Nasdaq Biotechnology ETF

0.17%

ProShares Ultra Nasdaq Biotechnology

0.17%

ARK Genomic Revolution ETF

佔比3.21%

ARK Innovation ETF

佔比1.71%

WisdomTree BioRevolution Fund

佔比1.69%

Global X Genomics & Biotechnology ETF

佔比1.68%

Virtus LifeSci Biotech Clinical Trials ETF

佔比0.73%

Franklin Genomic Advancements ETF

佔比0.53%

SPDR S&P Biotech ETF

佔比0.49%

Direxion Daily S&P Biotech Bull 3X Shares

佔比0.3%

Invesco Nasdaq Biotechnology ETF

佔比0.17%

ProShares Ultra Nasdaq Biotechnology

佔比0.17%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據